The endocrine system during sepsis

American Journal of the Medical Sciences

Volumn 328, Issue 4, 2004, Pages 238-247

  Brierre, Stephen ^a   Kumari, Rekha ^a   Deboisblanc, Bennett P ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Adrenal function; Cortisol; Euthyroid sick syndrome; Hyperglycemia; Insulin; Intensive care; Sepsis; Septic shock; Vasopressin

Indexed keywords

ADRENALIN; CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; DOBUTAMINE; DOPAMINE; FLUDROCORTISONE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; INSULIN; LIOTHYRONINE; METHYLPREDNISOLONE; MINERALOCORTICOID; NORADRENALIN; PHENYLEPHRINE; VASOPRESSIN;

ADRENAL CORTEX; ADRENAL FUNCTION; ADRENAL GLAND; CLINICAL TRIAL; DISEASE SEVERITY; ENDOCRINE DISEASE; ENDOCRINE SYSTEM; EUTHYROID SICK SYNDROME; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTENSIVE CARE; NEUROHYPOPHYSIS; PATHOGENESIS; PRESSOR RESPONSE; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE;

EID: 5644240779     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200410000-00007     Document Type: Article

References (82)

1. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes [comment]. J Clin Endocrinol Metab 2002;87:978-82.
2. Goldstein SA, Elwyn DH. The effects of injury and sepsis on fuel utilization. Annu Rev Nutr 1989;9:445-73.
3. Buczkowska EO. Alterations of blood glucose homeostasis during septic or injury stress-hyperglycemia [in Polish]. Wiad Lek 2002;55:731-44.
4. Chambrier C, Laville M, Rhzioual Berrada K, et al. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci 2000;99:321-8.
5. Lind L, Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intens Care 1994;5:100-5.
6. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogenous population of critically ill patients. Mayo Clin Proc 2003;78:1471-8.
7. Bagdade JD, Stewart M, Walters E. Impaired granulocyte adherence: a reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 1978;27:677-81.
8. Kjersem H, Hilsted J, Madsbad S, et al. Polymorphonuclear leucocyte dysfunction during short term metabolic changes from normo- to hyperglycemia in type 1 (insulin dependent) diabetic patients. Infection 1988;16:215-21.
9. Mazade MA, Edwards MS. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001;73:259-67.
10. McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995;9:1-9.
11. Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 1971;284:621-7.
12. Oldenborg PA, Sehlin J. Effects of D-glucose on chemokinesis and resting production of reactive oxygen species in neutrophil granulocytes of lean or obese-hyperglycemic mouse. Biosci Rep 1997;17:487-98.
13. Oldenborg PA, Sehlin J. Hyperglycemia in vitro attenuates insulin-stimulated chemokinesis in normal human neutrophils. Role of protein kinase C activation. J Leukoc Biol 1999;65:635-40.
14. Greenhalgh DG. Wound healing and diabetes mellitus. Clin Plastic Surg 2003;30:37-45.
15. Mohanty P, Hamouda W, Garg R, et al. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000;85:2970-3.
16. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72.
17. Hughes A, McVerry BA, Wilkinson L, et al. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983;69:254-9.
18. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8.
19. Taskinen MR. Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001;109(Suppl 2):S180-8.
20. Manzella D, Grella R, Marfella R, et al. Elevated post-prandial free fatty acids are associated with cardiac sympathetic overactivity in Type II diabetic patients. Diabetologia 2002;45:1737-8.
21. Spira A, Gowrishankar M, Halperin ML. Factors contributing to the degree of polyuria in a patient with poorly controlled diabetes mellitus. Am J Kidney Dis 1997;30:829-35.
22. Yu WK, Li WQ, Li N, et al. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations. World J Gastroenterol 2003;9:1824-7.
23. Golden SH, Peart-Vigilance C, Kao WH, et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999;22:1408-14.
24. Wilson SJ, Sexton DJ. Elevated preoperative fasting serum glucose levels increase the risk of postoperative mediastinitis in patients undergoing open heart surgery. Infect Control Hosp Epidemiol 2003;24:776-8.
25. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year (comment). J Am Coll Cardiol 1995;26:57-65.
26. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
27. Sodi-Pallares D, Testelli M, Fishleder F. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the EKG signs of myocardial infarction. Am J Cardiol 1962;9:166-81.
28. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control (comment). Crit Care Med 2003;31:359-66.
29. Van den Berghe G. Insulin therapy for the critically ill patient. Clin Cornerstone 2003;5:56-63.
30. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002;45:924-30.
31. Aljada A, Ghanim H, Mohanty P, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002;87:1419-22.
32. Finney SJ, Zekveld C, Elia A, et al. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041-7.
33. Trence DL, Kelly JL, Hirsch IB. The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab 2003;88:2430-7.
34. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003;361:1881-93.
35. Manlik S, Flores E, Lubarsky L, et al. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med 2003;31:1668-75.
36. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003;31:141-5.
37. Kenyon N. Defining adrenal insufficiency in septic shock. Crit Care Med 2003;31:321-3.
38. Annane D. Time for a consensus definition of corticosteroid insufficiency in critically ill patients. Crit Care Med 2003;31:1868-9.
39. Annane D, Sébille V, Troché G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotrophin. JAMA 2000;283:1038-45.
40. Rothwell P, Udwadia Z, Lawler P. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337:582-3.
41. Marik P, Rotello L, Zaloga G. Secondary adrenal insufficiency is common in critically ill patients. Crit Care Med 2001;29:A163.
42. Mamrahian A, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004;350:1629-38.
43. Bennett IL, Finland M, Hamburger M, et al. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963;183:166-9.
44. Shumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-41.
45. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 1984;311:1137-43.
46. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
47. Anonymous. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 1987;317:659-65.
48. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-9.
49. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
50. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46:589-97.
51. Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
52. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
53. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
54. Oelkers W, Diederich S, Bahr V. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992;75:259-64.
55. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
56. Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996;24:525-37.
57. Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock. Chest 1993;103:1826-31.
58. Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intens Care Med 1997;23:282-7.
59. Gregory JS, Bonfiglio MF, Dasta JF, et al. Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 1991;19:1395-400.
60. Parker MM, Shelhamer JH, Natanson C, et al. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987;15:923-9.
61. Chen SJ, Wu CC, Yang SN, et al. Hyperpolarization contributes to vascular hyperreactivity in rats with lipopolysaccharide-induced endotoxic shock. Life Sci 2000;68:659-68.
62. Medina P, Noguera I, Aldasoro M, et al. Enhancement by vasopressin of adrenergic responses in human mesenteric arteries. Am J Physiol 1997;272:H1087-93.
63. Hamu Y, Kanmura Y, Tsuneyoshi I, et al. The effects of vasopressin on endotoxin-induced attenuation of contractile responses in human gastroepiploic arteries in vitro. Anesth Analg 1999;88:542-8.
64. Malay MB, Burchell SA, Ashton RC, et al. Comparative physiologic effects of vasopressin, norepinephrine, and phenylephrine in the treatment of septic shock. Crit Care Med 1999;27:132A.
65. Sharshar T, Blanchard A, Paillard M, et al. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8.
66. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
67. Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
68. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497-500.
69. Luk J, Ajaelo I, Wong V, et al. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate. Am J Physiol 1993;265:R524-9.
70. Bunnell E, Parrillo JE. Cardiac dysfunction during septic shock. Clin Chest Med 1996;17:237-48.
71. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-82.
72. Malay MB, Ashton RC Jr, Landry DW, et al. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699-705.
73. Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-93.
74. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
75. Klinzing S, Simon M, Reinhart K, et al. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646-50.
76. Chopra IJ. Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 1997;82:329-34.
77. Slag MF, Morley JE, Elson MK, et al. Hypothyroxenemia in critically ill patients as predictor of high mortality. JAMA 1981;245:43-5.
78. Wiersinga WM. Nonthyroidal illness. In: Braverman LE, Utiger RD, editors. Werner & Ingbar's The thyroid: a fundamental and clinical text. Baltimore: Lippincott Williams & Wilkins; 2000. p. 121.
79. Mullis-Jansson SL, Argenziano M, Corwin S, et al. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999;117:1128-34.
80. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary artery bypass surgery. N Engl J Med 1995;333:1522.
81. Bennet-Guerrero E, Jimenez JL, White WD, et al. Cardiovascular effect of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery: randomized, double blind placebo controlled trial. JAMA 1996;275:687-92.
82. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986;63:1-8.